Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lorna Hopcroft"'
Autor:
Thomas G. Hayhow, Beth Williamson, Mandy Lawson, Natalie Cureton, Erin L. Braybrooke, Andrew Campbell, Rodrigo J. Carbajo, Azadeh Cheraghchi-Bashi, Elisabetta Chiarparin, Coura R. Diène, Charlene Fallan, David I. Fisher, Frederick W. Goldberg, Lorna Hopcroft, Philip Hopcroft, Anne Jackson, Jason G. Kettle, Teresa Klinowska, Ulrike Künzel, Gillian Lamont, Hilary J. Lewis, Gareth Maglennon, Scott Martin, Pablo Morentin Gutierrez, Christopher J. Morrow, Myria Nikolaou, J. Willem M. Nissink, Patrick O’Shea, Radoslaw Polanski, Markus Schade, James S. Scott, Aaron Smith, Judith Weber, Joanne Wilson, Bin Yang, Claire Crafter
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-17 (2024)
Abstract Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROT
Externí odkaz:
https://doaj.org/article/ec006f9560824ea494be6041bb1eeb60
Autor:
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors. How
Externí odkaz:
https://doaj.org/article/216706db2e6b4b6eae15d98244910c27
Autor:
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/597341a4bba64230b85546c506522cc0
Autor:
Aarti Kawatkar, Roger A. Clark, Lorna Hopcroft, Debora Ann Roaquin, Ronald Tomlinson, Andrea M. Zuhl, Gillian M. Lamont, Jason G. Kettle, Susan E. Critchlow, M. Paola Castaldi, Frederick W. Goldberg, Andrew X. Zhang
Publikováno v:
ACS chemical biology.
Lactic acid transport is a key process maintaining glycolytic flux in tumors. Inhibition of this process will result in glycolytic shutdown, impacting on cell growth and survival and thus has been pursued as a therapeutic approach for cancers. Using
Autor:
Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont, David Buttar, Attilla K. T. Ting, Thomas M. McGuire, Calum R. Cook, David Beattie, Pablo Morentin Gutierrez, Stefan L. Kavanagh, Jasper C. Komen, Aarti Kawatkar, Roger Clark, Lorna Hopcroft, Gareth Hughes, Susan E. Critchlow
Publikováno v:
Journal of medicinal chemistry.
Due to increased reliance on glycolysis, which produces lactate, monocarboxylate transporters (MCTs) are often upregulated in cancer. MCT4 is associated with the export of lactic acid from cancer cells under hypoxia, so inhibition of MCT4 may lead to
Autor:
Stephen Green, Armelle Logie, Nichola Whalley, Nicola Curtis, Kate Byth, Haihong Zhong, Clare Murray, Mike Firth, Lorna Hopcroft, Lorraine Mooney, Filippos Michopoulos, Paul D. Smith, Amanda Benjamin, Mitchell Revill, Susan E. Critchlow
Publikováno v:
Oncotarget
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen G
Autor:
Lorna Hopcroft, Matthew A. King, Elizabeth Hardaker, Frederick W. Goldberg, Martin R. Brown, Beverley Hammond, Anna Staniszewska, Jenna Bradley, Filippos Michopoulos, Gareth Hughes, Larissa S. Carnevalli, Pablo Morentin-Gutierrez, Susan E. Critchlow
Publikováno v:
Cancer Research. 79:1207-1207
Metabolic adaptation to a Warburg phenotype is a hallmark of cancer, where tumors rely on glucose to produce ATP and building blocks required to support rapid tumor growth. Glycolytic metabolism requires continuous export of lactate from cells by mon
Autor:
Liang Xie, Jingchuan Zhang, Lorraine Mooney, Nicola Curtis, De-Hua Yu, Haihong Zhong, Clare Murray, Paul D. Smith, Nicky Whalley, Armelle Logie, Lorna Hopcroft, Susan E. Critchlow, Mitchell Revill
Publikováno v:
Cancer Research. 72:3224-3224
Introduction - The metabolic phenotype of tumours (relative to most normal tissues) is shifted from oxidative phosphorylation to aerobic (Warburg Effect) or anaerobic glycolysis. This enables tumours to meet their energetic and biosynthetic demands e